News

Treatment with Kalydeco (ivacaftor) led to improved lung function and weight gain as well as fewer respiratory infections and hospitalizations among cystic fibrosis (CF) patients with certain CFTR gating mutations, according to a real-world study. “These results support the long-term effectiveness and use of ivacaftor [Kalydeco] for the…

Instead of stopping Trikafta treatment, reducing the dose and providing psychological support may reduce or resolve mental health side effects, including depression, anxiety, and brain fog in patients with cystic fibrosis (CF), a new study reports. “It was reassuring that dose adjustments, in conjunction with psychological support and…

Treatment with PP-007 — a compound known to promote the release of anti-inflammatory carbon monoxide (CO) gas — significantly reduced the levels of pro-inflammatory immune cells and molecules in the lungs of a mouse model of cystic fibrosis (CF), a study shows. These benefits were associated with an increased production…

Stool consistency and frequency were healthy for the majority of infants with cystic fibrosis (CF) in the first year of life, according to an analysis of data from the BONUS study. Stool consistency and frequency were not associated with pain, while infants exclusively fed with formula or who received…

Researchers at Stanford University have been awarded £210,000 (about $265,000) to study preventing hearing loss caused by a class of antibiotics, called aminoglycosides, that are commonly used to treat lung infections in people with cystic fibrosis (CF). The three-year research project will be jointly funded by the Royal…

A $2.7 million grant from the National Heart, Lung, and Blood Institute, part of the National Institutes of Health (NIH), has been awarded to two stem cell researchers at the University of Houston investigating an alternative cause of chronic lung inflammation in people with cystic fibrosis (CF). The project,…

People from ethnic minority backgrounds were significantly less likely to be eligible for the cystic fibrosis therapy Kaftrio (ivacaftor/tezacaftor/elexacaftor) than white patients, according to a recent U.K. study. Given that the therapy is the most effective CF therapy on the market, “the CF community should urgently address the…

Several potential biomarkers of nontuberculosis mycobacteria (NTM)-associated lung disease were identified in the breath of people with cystic fibrosis (CF) in a recent pilot study. The approach may offer a faster way of reaching an NTM diagnosis, which has historically relied on slow bacterial culture techniques that sometimes delay…

Certain variations in the gene that codes for the inflammatory signaling molecule TGF-beta1 are associated with faster lung function decline and a higher risk of Pseudomonas infections for people with cystic fibrosis (CF), a new study indicates. “Our results demonstrate the relevance of the multifunctional cytokine [signaling molecule]…

A detailed analysis of lung tissue of cystic fibrosis (CF) patients found specific changes to the extracellular matrix (ECM), the three-dimensional network of molecules and proteins outside the cell that supports lung function, a study showed. Drivers of ECM breakdown may act as therapeutic targets or biomarkers to monitor…